Search
+
    SEARCHED FOR:

    SOFOSBUVIR

    Rs 78,400 vs Rs 7,750 medicine: Novartis, Eli Lilly oppose bid to cut breast cancer drug prices in India

    Novartis and Eli Lilly have opposed a Kerala High Court petition seeking government intervention to make two breast cancer drugs cheaper, despite their India sales accounting for less than 0.5% of global revenues. Court submissions have highlighted development, clinical-trial and manufacturing costs against the medicines’ prices in India.

    Mylan set to use hepatitis C combo drugs in COVID-19 phase-2 trials

    The SEC on Covid-19 permitted the company to conduct phase-II trials with caveats such as that the participants should not be more than 65 years of age. It also asked the company to add more government sites and that the sites should be geographically distributed. The company has also been told to appoint a drug safety monitoring board.

    Natco Pharma launches Hepatitis C drug in India

    Natco Pharma launched fixed dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C under the brand name Hepcinat Plus.

    Natco Pharma launches generic hepatitis C drug in India

    The company has launched a generic version of sofosbuvir 400 mg/velpatasvir 100 mg fixed dose combination in India under the brand name 'Velpanat'.

    Hetero gets DCGI nod for generic chronic hepatitis C drug

    The company "has received the approval for the generic version of 'Sofosbuvir+Velpatasvir' combination from the Drugs Controller General of India", Hetero said.

    Gilead Sciences withdraws writ petition in support of consolidating hearings over patent rights

    Legal experts questioned Gilead's decision to take up the matter at the Delhi HC, saying it ought to have directly approached the Kolkata Patent Office.

    The Economic Times
    BACK TO TOP